


RU 58841

Cat. No.:	HY-10561		
CAS No.:	154992-24-2		
Molecular Formula:	C ₁₇ H ₁₈ F ₃ N ₃ O ₃		
Molecular Weight:	369.34		
Target:	Androgen Receptor		
Pathway:	Vitamin D Related/Nuclear Receptor		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (270.75 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.7075 mL	13.5377 mL	27.0753 mL
	5 mM	0.5415 mL	2.7075 mL	5.4151 mL
	10 mM	0.2708 mL	1.3538 mL	2.7075 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

RU 58841 (PSK-3841) is a specific androgen receptor antagonist or anti-androgen. RU 58841 has a dramatic effect on hair regrowth^{[1][2][3]}.

IC₅₀ & Target

Androgen receptor

In Vitro

RU 58841 (100 nM) inhibits DHT's effects (agonistic effects on the wt AR) in PC3 cells with the wt AR^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

RU 58841 (applied topically, 1% in ethanol) increases hair growth rates (LHGR) in balding samples grafted on to testosterone-conditioned nude mice^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Pan HJ, et al. Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stump-tailed macaques. *Endocrine*. 1998 Aug;9(1):39-43.

[2]. A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice. By De Brouwer, B.; Tetelin, C.; Leroy, T.; Bonfils, A.; Van Neste, D. *British Journal of Dermatology* (1997), 137(5), 699-702.

[3]. Münster U, Nakamura C, Haberland A, Jores K, Mehnert W, Rummel S, Schaller M, Korting HC, Zouboulis ChC, Blume-Peytavi U, Sch?fer-Korting M. RU 58841-myristate--prodrug development for topical treatment of acne and androgenetic alopecia. *Pharmazie*. 2005 Jan;60(1):8-12.

[4]. Battmann T, Bonfils A, Branche C, Humbert J, Goubet F, Teutsch G, Philibert D. RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism. *J Steroid Biochem Mol Biol*. 1994 Jan;48(1):55-60.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA